The report evaluates the analytical validity, clinical validity, and clinical utility of the ColonSentry liquid biopsy test, a gene expression assay intended to estimate the current relative risk of having colorectal cancer (CRC) for patients eligible for CRC screening.
Precision Medicine
The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:
- Will testing change patient management for this indication?
- If so, what tests and/or therapies should I use?
- Should we cover testing and/or therapies?
- Can we manage these services internally?
- Precision Medicine Insights
- Precision Medicine Research Briefs
FilmArray Respiratory Panel (BioFire Diagnostics LLC)
This report evaluates the analytical validity, clinical validity, and clinical utility of the FilmArray Respiratory Panel.
Oncotype DX Breast Recurrence Score (Genomic Health Inc.) for Lymph Node–Positive Patients
This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX Breast Recurrence Score test.
Pharmacogenetic and Pharmacogenomic Testing to Improve Outcomes Related to Opioid Use Disorder
This report evaluates the clinical utility of pharmacogenetic and pharmacogenomic testing for (1) gene variants to predict risk of opioid dependency in patients being treated for pain or (2) gene variants to improve treatment of patients with diagnosed opioid use disorder (OUD).
Pharmacogenetic and Pharmacogenomic Testing to Improve Outcomes Related to Opioid Use Disorder
This report evaluates the clinical utility of pharmacogenetic and pharmacogenomic testing for (1) gene variants to predict risk of opioid dependency in patients being treated for pain or (2) gene variants to improve treatment of patients with diagnosed opioid use disorder (OUD).
Oncotype DX Breast Recurrence Score for Lymph Node–Negative Patients (Genomic Health Inc.)
This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX Breast Recurrence Score testfor patients diagnosed with estrogen receptor–positive, human epidermal growth factor 2–negative, and node-negative invasive breast cancer.
Liquid Biopsy Tests for Colorectal Cancer Screening
This report evaluates the clinical utility of liquid biopsy tests for colorectal cancer (CRC) screening to reduce CRC morbidity and mortality.
FilmArray Respiratory Panel 2 (BioFire Diagnostics LLC)
This report evaluates the analytical validity, clinical validity, and clinical utility of the FilmArray Respiratory Panel 2.
Envisia Genomic Classifier (Veracyte)
This report evaluates the analytical validity, clinical validity, and clinical utility of the Envisia Genomic Classifier.
Pharmacogenetic Testing to Guide Codeine or Tramadol Prescribing for Pain in Pediatric Patients
This report evaluates the clinical utility of pharmacogenetic testing for CYP2D6 gene variants prior to prescribing codeine or tramadol to improve opioid treatment–related outcomes in pediatric patients with organic causes of pain.